

#3 2/19/02

3973 U.S. PTO
10/072301
02/06/02

EXPRESS MAIL CERTIFICATE			
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Fedelia Torres	Express Mail No.	EL923480401US
Signature	<i>Fedelia Torres</i>	Date	February 6, 2002

INFORMATION DISCLOSURE STATEMENT Address to: Box Patent Application Commissioner for Patents Washington, D.C. 20231	Attorney Docket	GLAD001CON
	First Named Inventor	GOLDSMITH
	Application Number	To Be Assigned
	Filing Date	February 6, 2002
	Group Art Unit	To Be Assigned
	Examiner Name	To Be Assigned
	Title	TRANSGENIC RODENTS AND RODENT CELL LINES EXPRESSING HIV CO-RECEPTORS

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO/SB/08A- listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

Use the following if submitting IDS with a continuing application:

All of the references identified herein were disclosed in parent application Serial No. 09/470,817 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except as noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants are filing this Disclosure Statement at the time of filing the application, no fee is required.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Feb 6, 2002

By: *Kathleen S. Hall*
Kathleen S. Hall
Registration No. 44,143

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	To Be Assigned	
Sheet		1	of	2	Filing Date	Feb. 6, 2002 (herewith)
					First Named Inventor	GOLDSMITH
					Group Art Unit	To Be Assigned
					Examiner Name	To Be Assigned
					Attorney Docket Number	GLAD001CON

JC978 U.S. PTO
 10/072381
 02/06/02

U.S. PATENT DOCUMENTS						
Examin er Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,939,320		Littman et al.	08/17/1999	
		5,529,765		Kindt et al	06/25/1996	

FOREIGN PATENT DOCUMENTS							
Examin er Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
			WO/98/18826			05/07/1998	
			WO/98/58536			12/30/1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	To Be Assigned		
		Filing Date	February 6, 2002		
		First Named Inventor	GOLDSMITH		
		Group Art Unit	To Be Assigned		
		Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	GLAD001CON

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DENG, et al., <i>Nature</i> 381:661-666 (1996)	
		DUNN, C.S., et al., <i>J. Gen. Virol.</i> 76 (Pt 6):1327-1336 (1995)	
		FENG, et al., <i>Science</i> 272:872-877 (1996)	
		GILLESPIE, F.P., et al., <i>Mol. Cell Biol.</i> 13:2952-2958 (1993)	
		LENO, M. et al., <i>Virology</i> 213:450-454 (1995)	
		LORES et al., (1992) <i>AIDS Res. Hum. Retroviruses</i> 8:2063	
		SPECK et al., (1997) <i>J. of Virol</i> 71(9):7136-7139	
		BROWNING et al. (December 1997), "Mice Transgenic for Human CD4 and CCR5 are Susceptible to HIV Infection," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 94:14637-14641.	
		SPECK et al. (July 1998), "Rabbit Cells Expressing Human CD4 and Human CCR5 are Highly Permissive for Human Immunodeficiency Virus Type 1 Infection," <i>Journal of Virology</i> , Vol. 72(7):5728-5734.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.